• +1-646-491-9876
    • +91-20-67278686

    Search

    Aplastic Anemia Pipeline Review H1 2017

    Aplastic Anemia Pipeline Review H1 2017

    • Report Code ID: RW0001799266
    • Category Pharmaceuticals
    • No. of Pages 79
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Aplastic Anemia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H1 2017, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

    Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1, 1 and 5 respectively.

    Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Aplastic Anemia - Overview
    Aplastic Anemia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Aplastic Anemia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Aplastic Anemia - Companies Involved in Therapeutics Development
    3SBio Inc
    Acceleron Pharma Inc
    Amgen Inc
    BioLineRx Ltd
    F. Hoffmann-La Roche Ltd
    Gamida Cell Ltd
    Novartis AG
    Pluristem Therapeutics Inc
    Regen BioPharma Inc
    Aplastic Anemia - Drug Profiles
    Anemir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BL-8040 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Aplastic Anemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CordIn - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eltrombopag olamine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HemaXellerate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLXR-18 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    romiplostim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sotatercept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    thrombopoietin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aplastic Anemia - Dormant Projects
    Aplastic Anemia - Discontinued Products
    Aplastic Anemia - Product Development Milestones
    Featured News & Press Releases
    Apr 20, 2017: NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
    Oct 24, 2016: Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, for treatment of Bone Marrow Suppression Study
    Sep 22, 2016: Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy
    Aug 25, 2016: Health Canada issues advisory on REVOLADE citing risk of severe hepatotoxicity
    May 11, 2016: Regen BioPharma Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
    May 03, 2016: Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients
    Jan 26, 2016: Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
    Dec 15, 2015: Regen BioPharma Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
    Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
    Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
    Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology's Annual Meeting
    Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate
    Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia
    Sep 02, 2015: Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia
    Jul 24, 2015: Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Aplastic Anemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Aplastic Anemia - Pipeline by 3SBio Inc, H1 2017
    Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H1 2017
    Aplastic Anemia - Pipeline by Amgen Inc, H1 2017
    Aplastic Anemia - Pipeline by BioLineRx Ltd, H1 2017
    Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Aplastic Anemia - Pipeline by Gamida Cell Ltd, H1 2017
    Aplastic Anemia - Pipeline by Novartis AG, H1 2017
    Aplastic Anemia - Pipeline by Pluristem Therapeutics Inc, H1 2017
    Aplastic Anemia - Pipeline by Regen BioPharma Inc, H1 2017
    Aplastic Anemia - Dormant Projects, H1 2017
    Aplastic Anemia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Aplastic Anemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    3SBio Inc
    Acceleron Pharma Inc
    Amgen Inc
    BioLineRx Ltd
    F. Hoffmann-La Roche Ltd
    Gamida Cell Ltd
    Novartis AG
    Pluristem Therapeutics Inc
    Regen BioPharma Inc

    Request for Sample

    Report Url http://www.reportsweb.com//aplastic-anemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//aplastic-anemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//aplastic-anemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments